Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Rhea-AI Summary

Surrozen, Inc. (Nasdaq: SRZN) will report its Q4 and full year 2022 financial results on March 22, 2023, after the U.S. markets close. The company will also provide a corporate and pipeline progress update during a live audio webcast at 4:30 PM ET. Interested participants can access the webcast via the Investor website. Surrozen is a clinical-stage biotechnology firm focused on developing drug candidates that selectively modulate the Wnt pathway, targeting conditions like inflammatory bowel disease, severe liver issues, and eye diseases.

Positive

• Upcoming Q4 and full year 2022 financial results report anticipated on March 22, 2023.
• Live audio webcast for detailed corporate and pipeline updates scheduled.

Negative

• None.

News Market Reaction – SRZN

+21.18%

+21.18% Session move

In the trading session that priced this news, SRZN gained 21.18%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress.

Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast.

About Surrozen
Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on inflammatory bowel, severe liver, and eye diseases. For more information, please visit surrozen.com.

Investor Contact:
Investorinfo@surrozen.com

FAQ

When will Surrozen report its financial results for Q4 and full year 2022?

Surrozen will report its Q4 and full year 2022 financial results on March 22, 2023.

What time is the Surrozen corporate update webcast scheduled for?

The Surrozen corporate update webcast is scheduled for 4:30 PM Eastern Time on March 22, 2023.

How can I join the Surrozen investor webcast?

You can join the Surrozen investor webcast via their Investor website.

What is the focus of Surrozen's drug development?

Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, targeting diseases such as inflammatory bowel disease, severe liver issues, and eye diseases.